 |
21 Diseases |  |
0 Trials |
|
0 Trials |  |
22 News |  |
- || sembragiline (RO4602522) / Roche, Evotec
Review, Journal: Development and Clinical Application of Positron Emission Tomography Imaging Agents for Monoamine Oxidase B. (Pubmed Central) - Mar 15, 2022
Important applications of [C]L-deprenyl-D2 PET are detecting a 40% loss in radiotracer accumulation in cigarette smokers, and substantial occupancy of novel therapeutics like EVT301 and sembragiline. Given the number of diseases with elevations of MAO-B density and astrogliosis, and the advance of [C]SL25.1188, clinical applications of MAO-B imaging are still at an early stage.
- |||| sembragiline (RO4602522) / Roche, Evotec
Trial completion: MAyflOwer RoAD: A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy (clinicaltrials.gov) - Mar 14, 2016
P2, N=531, Completed, Sponsor: Hoffmann-La Roche
Given the number of diseases with elevations of MAO-B density and astrogliosis, and the advance of [C]SL25.1188, clinical applications of MAO-B imaging are still at an early stage. Active, not recruiting --> Completed
- ||| sembragiline (RO4602522) / Roche, Evotec
Trial completion: A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval (clinicaltrials.gov) - Oct 17, 2014
P1, N=203, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Completed
- || sembragiline (RO4602522) / Roche, Evotec
Trial primary completion date: A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval (clinicaltrials.gov) - May 18, 2014
P1, N=183, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Trial primary completion date: Sep 2014 --> Aug 2014
- | sembragiline (RO4602522) / Roche, Evotec
Trial completion date: A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval (clinicaltrials.gov) - May 18, 2014
P1, N=183, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Sep 2014 --> Aug 2014 Trial completion date: Sep 2014 --> Aug 2014
- ||| sembragiline (RO4602522) / Roche, Evotec
Enrollment closed: MAyflOwer RoAD: A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy (clinicaltrials.gov) - May 11, 2014
P2, N=544, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Sep 2014 --> Aug 2014 Recruiting --> Active, not recruiting
- || sembragiline (RO4602522) / Roche, Evotec
Trial initiation date: A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval (clinicaltrials.gov) - May 11, 2014
P1, N=183, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Initiation date: Mar 2014 --> Apr 2014
- ||| sembragiline (RO4602522) / Roche, Evotec
New P1 trial: A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval (clinicaltrials.gov) - Apr 2, 2014
P1, N=183, Recruiting, Sponsor: Hoffmann-La Roche
- sembragiline (RO4602522) / Roche, Evotec
Enrollment change: A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers (clinicaltrials.gov) - Oct 20, 2013
P1, N=17, Completed, Sponsor: Hoffmann-La Roche
Initiation date: Mar 2014 --> Apr 2014 N=24 --> 17
- | sembragiline (RO4602522) / Roche, Evotec
Trial completion: A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers (clinicaltrials.gov) - Oct 20, 2013
P1, N=17, Completed, Sponsor: Hoffmann-La Roche
N=24 --> 17 Recruiting --> Completed
- | sembragiline (RO4602522) / Roche, Evotec
Trial completion: A Study of The Effects of Multiple Doses of Ketoconazole on Single Dose Pharmacokinetics of RO4602522 in Healthy Male Volunteers (clinicaltrials.gov) - Feb 3, 2013
P1, N=34, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Active, not recruiting --> Completed
- sembragiline (RO4602522) / Roche, Evotec
Trial completion: A Single Dose Study of Radiolabeled RO4602522 in Healthy Volunteers (clinicaltrials.gov) - Oct 23, 2012
P1, N=6, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Completed
- | sembragiline (RO4602522) / Roche, Evotec
New P1 trial: A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers (clinicaltrials.gov) - Oct 2, 2012
P1, N=17, Completed, Sponsor: Hoffmann-La Roche
- |||| sembragiline (RO4602522) / Roche, Evotec
Enrollment open: MAyflOwer RoAD: A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy (clinicaltrials.gov) - Sep 13, 2012
P2, N=495, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| sembragiline (RO4602522) / Roche, Evotec
New P2 trial: MAyflOwer RoAD: A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy (clinicaltrials.gov) - Aug 30, 2012
P2, N=495, Recruiting, Sponsor: Hoffmann-La Roche
- sembragiline (RO4602522) / Roche, Evotec
New P1 trial: A Single Dose Study of Radiolabeled RO4602522 in Healthy Volunteers (clinicaltrials.gov) - Jun 27, 2012
P1, N=6, Completed, Sponsor: Hoffmann-La Roche
- | sembragiline (RO4602522) / Roche, Evotec
New P1 trial: A Study of The Effects of Multiple Doses of Ketoconazole on Single Dose Pharmacokinetics of RO4602522 in Healthy Male Volunteers (clinicaltrials.gov) - Jun 19, 2012
P1, N=34, Completed, Sponsor: Hoffmann-La Roche